Tadehaginoside modulates lipogenesis and glucose consumption in HepG2 cells

Abstract

Tadehaginoside (TS) is a phenylpropanoid glycoside found in Tadehagi triquetrum, a medicinal plant with multiple biological activities. This study investigated the effect of TS on lipogenesis and glucose consumption in HepG2 cells. Treatment with TS inhibited lipid accumulation in a dose-dependent manner. This inhibition was closely associated with the downregulation of lipogenic genes such as SREBP-1a, SREBP-2 and their downstream targets (FAS, ACC, HMGR) and the upregulation of lipolytic gene PPARα as revealed by real-time quantitative PCR. Further investigation showed that TS significantly stimulated glucose consumption by HepG2 cells and glucose uptake by C2C12 myotubes, which could be partially explained by the upregulation of PPARγ. Collectively, these results clearly indicate that TS is an effective regulator of lipogenesis and glucose consumption, which could be useful in treatment of obesity and diabetes.